# Sandy Mou

> Sandy Mou, MD, is the Chief Executive Officer and Board Executive Director of CORXEL Pharmaceuticals, a New Jersey- and Shanghai-linked biotech developing an oral small molecule GLP-1 receptor agonist for obesity and diabetes. A Fudan-trained clinician turned pharma executive with nearly three decades at GSK, AstraZeneca, Johnson & Johnson, and MSD, she led MSD China's oncology unit into the country's top three within three years and later took Shanghai Allist public on the STAR Market before joining JIXING - now CORXEL - in early 2023.

- **Role:** Chief Executive Officer and Board Executive Director at CORXEL Pharmaceuticals
- **Organizations:** CORXEL Pharmaceuticals, JIXING Pharmaceuticals, Shanghai Allist Pharmaceutical Technology, MSD China, Johnson & Johnson Medical, Xi'an Janssen, AstraZeneca, GSK
- **Nationality:** Chinese
- **Education:** Bachelor of Medicine, Shanghai Medical College of Fudan University, EMBA, China Europe International Business School (CEIBS)
- **Known for:** Grew MSD China oncology into a top-three multinational oncology business in three years, Led Allist to STAR Market IPO on the Shanghai Stock Exchange, Delivered Allist's first new drug approval and reimbursement listing

## Career timeline

- **early career** — Practiced as a clinician for seven years after graduating from Fudan
- **1990s-2010s** — Held management positions at GSK, AstraZeneca, Xi'an Janssen, J&J Medical
- **2017** — Joined MSD China to establish the oncology business unit; oversaw the Keytruda launch
- **2020** — Became CEO of Shanghai Allist Pharmaceutical Technology
- **2020-2022** — Led Allist to a STAR Market listing on Shanghai Stock Exchange and first new drug approval
- **2022-12** — Announced as incoming CEO of JIXING Pharmaceuticals
- **2023-01** — Officially took over as CEO of JIXING (later CORXEL)
- **2024** — CORXEL acquired worldwide (ex-Greater China) rights to CX11, an oral GLP-1 receptor agonist, from Vincentage
- **2026-01** — Closed $287M Series D1 financing to fund CX11 Phase 2/3 obesity studies

## Achievements

- Grew MSD China oncology into a top-three multinational oncology business in three years
- Led Allist to STAR Market IPO on the Shanghai Stock Exchange
- Delivered Allist's first new drug approval and reimbursement listing
- Closed $287M Series D1 for CORXEL in January 2026
- Secured global ex-China rights to CX11 oral GLP-1 program

## Latest updates

- **2026-01** — CORXEL closed $287M Series D1 financing to fund CX11 Phase 2/3 obesity studies.
- **2024** — CORXEL acquired ex-Greater China rights to CX11 from Vincentage.

## Links

- Website: https://www.corxelbio.com/
- LinkedIn: https://www.linkedin.com/in/sandy-mou-987557345/

---

Profile page: https://yespress.io/sandy-mou
Published by YesPress — https://yespress.io
Last updated: 2026-07-08